EPIX vs. AKBA, HOWL, RAPT, ENTA, VNDA, RENB, CTNM, VRCA, ERAS, and NBTX
Should you be buying ESSA Pharma stock or one of its competitors? The main competitors of ESSA Pharma include Akebia Therapeutics (AKBA), Werewolf Therapeutics (HOWL), RAPT Therapeutics (RAPT), Enanta Pharmaceuticals (ENTA), Vanda Pharmaceuticals (VNDA), Renovaro (RENB), Contineum Therapeutics (CTNM), Verrica Pharmaceuticals (VRCA), Erasca (ERAS), and Nanobiotix (NBTX). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, community ranking, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Akebia Therapeutics received 62 more outperform votes than ESSA Pharma when rated by MarketBeat users. However, 76.32% of users gave ESSA Pharma an outperform vote while only 64.06% of users gave Akebia Therapeutics an outperform vote.
In the previous week, Akebia Therapeutics had 2 more articles in the media than ESSA Pharma. MarketBeat recorded 2 mentions for Akebia Therapeutics and 0 mentions for ESSA Pharma. ESSA Pharma's average media sentiment score of 0.00 equaled Akebia Therapeutics'average media sentiment score.
ESSA Pharma has lower revenue, but higher earnings than Akebia Therapeutics. ESSA Pharma is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.
Akebia Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 259.71%. ESSA Pharma has a consensus target price of $16.50, indicating a potential upside of 157.81%. Given ESSA Pharma's higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than ESSA Pharma.
ESSA Pharma has a net margin of 0.00% compared to ESSA Pharma's net margin of -26.32%. ESSA Pharma's return on equity of 0.00% beat Akebia Therapeutics' return on equity.
33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 75.1% of ESSA Pharma shares are held by institutional investors. 3.8% of Akebia Therapeutics shares are held by company insiders. Comparatively, 14.7% of ESSA Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Akebia Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.
Summary
Akebia Therapeutics beats ESSA Pharma on 8 of the 15 factors compared between the two stocks.
Get ESSA Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ESSA Pharma Competitors List
Related Companies and Tools
